Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin (Nature Communications (2018) DOI: 10.1038/s41467-017-02733-4);Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  DeWaal, Dannielle ^a   Nogueira, Veronique ^a   Terry, Alexander R ^a   Patra, Krushna C ^a,d   Jeon, Sang Min ^a,e   Guzman, Grace ^a   Au, Jennifer ^c   Long, Christopher P ^c   Antoniewicz, Maciek R ^c   Hay, Nissim ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOKINASE; HEXOKINASE; HEXOKINASE 2; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; PYRUVIC ACID; SERINE; SHORT HAIRPIN RNA; SORAFENIB; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; HEXOKINASE 2, HUMAN; HEXOKINASE 2, MOUSE; NICOTINAMIDE;

CELL; CHEMICAL REACTION; ENZYME; ENZYME ACTIVITY; GLUCOSE; GROWTH; INHIBITION; INHIBITOR; ION; SECRETION; TUMOR; VULNERABILITY;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIZATION; DYSPLASIA; ECTOPIC EXPRESSION; GENE SILENCING; GLUCOSE METABOLISM; GLYCOLYSIS; HEP-G2 CELL LINE; HUH-7 CELL LINE; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PROTEIN DEPLETION; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; DRUG SCREENING; ENZYMOLOGY; LIVER TUMOR; METABOLIC FLUX ANALYSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; GLYCOLYSIS; HEP G2 CELLS; HEXOKINASE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; MALE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; METABOLIC FLUX ANALYSIS; METFORMIN; MICE, NUDE; MOLECULAR TARGETED THERAPY; NIACINAMIDE; OXIDATIVE PHOSPHORYLATION; PHENYLUREA COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85041281529     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-04182-z     Document Type: Erratum

References (31)

1. Cabibbo, G., Latteri, F., Antonucci, M. & Craxi, A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 6, 159-169 (2009).
2. Singh, S., Singh, P. P., Roberts, L. R. & Sanchez, W. Chemopreventive strategies in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 11, 45-54 (2014).
3. Hay, N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat. Rev. Cancer 16, 635-649 (2016).
4. Robey, R. B. & Hay, N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25, 4683-4696 (2006).
5. Wilson, J. E. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol. 206, 2049-2057 (2003).
6. Guo, C. et al. Coordinated regulatory variation associated with gestational hyperglycaemia regulates expression of the novel hexokinase HKDC1. Nat. Commun. 6, 6069 (2015).
7. Pedersen, P. L., Mathupala, S., Rempel, A., Geschwind, J. F. & Ko, Y. H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 1555, 14-20 (2002).
8. Guzman, G. et al. Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig. Dis. Sci. 60, 420-426 (2015).
9. Patra, K. C. et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 24, 213-228 (2013).
10. Ahler, E. et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS ONE 8, e64561 (2013).
11. O'Rear, J. L., Scocca, J. R., Walker, B. K., Kaiden, A. & Krag, S. S. Chinese hamster ovary cells with reduced hexokinase activity maintain normal GDP-mannose levels. J. Cell Biochem. 72, 56-66 (1999).
12. Luengo, A., Sullivan, L. B. & Heiden, M. G. Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol. 12, 82 (2014).
13. Pernicova, I. & Korbonits, M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10, 143-156 (2014).
14. Sofer, A., Lei, K., Johannessen, C. M. & Ellisen, L. W. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell. Biol. 25, 5834-5845 (2005).
15. Brugarolas, J. et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893-2904 (2004).
16. Cesar, M. d. C. & Wilson J. E. Further studies on the coupling of mitochondrially bound hexokinase to intramitochondrially compartmented ATP, generated by oxidative phosphorylation. Arch. Biochem. Biophys. 350, 109-117 (1998).
17. Schug, Z. T., Vande Voorde, J. & Gottlieb, E. The nurture of tumors can drive their metabolic phenotype. Cell. Metab. 23, 391-392 (2016).
18. Yuneva, M. O. et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell. Metab. 15, 157-170 (2012).
19. Zhang, L. et al. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51, 913-921 (1997).
20. Ben Sahra, I. et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71, 4366-4372 (2011).
21. Kalender, A. et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell. Metab. 11, 390-401 (2010).
22. Puisieux, A. et al. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J. 7, 1407-1413 (1993).
23. Lin, H. et al. Discovery of a novel 2,6-disubstituted glucosamine series of potent and selective hexokinase 2 inhibitors. ACS Med. Chem. Lett. 7, 217-222 (2016).
24. Ahn, W. S. & Antoniewicz, M. R. Parallel labeling experiments with [1,2-(13)C] glucose and [U-(13)C]glutamine provide new insights into CHO cell metabolism. Metab. Eng. 15, 34-47 (2013).
25. Antoniewicz, M. R., Kelleher, J. K. & Stephanopoulos, G. Accurate assessment of amino acid mass isotopomer distributions for metabolic flux analysis. Anal. Chem. 79, 7554-7559 (2007).
26. Fernandez, C. A., Des Rosiers, C., Previs, S. F., David, F. & Brunengraber, H. Correction of 13C mass isotopomer distributions for natural stable isotope abundance. J. Mass Spectrom. 31, 255-262 (1996).
27. Yoo, H., Antoniewicz, M. R., Stephanopoulos, G. & Kelleher, J. K. Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. J. Biol. Chem. 283, 20621-20627 (2008).
28. Gebreselassie, N. A. & Antoniewicz, M. R. (13)C-metabolic flux analysis of co-cultures: a novel approach. Metab. Eng. 31, 132-139 (2015).
29. Ahn, W. S., Crown, S. B. & Antoniewicz, M. R. Evidence for transketolase-like TKTL1 flux in CHO cells based on parallel labeling experiments and (13)C-metabolic flux analysis. Metab. Eng. 37, 72-78 (2016).
30. Antoniewicz, M. R., Kelleher, J. K. & Stephanopoulos, G. Determination of confidence intervals of metabolic fluxes estimated from stable isotope measurements. Metab. Eng. 8, 324-337 (2006).
31. Wang, Q. et al. Spontaneous hepatocellular carcinoma after the combined deletion of Akt isoforms. Cancer Cell 29, 523-535 (2016).